Analyst consensus rating

Keros Therapeutics Analyst Rating: Buy

Direct answer

Keros Therapeutics's consensus rating is Buy.

6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.00.
Forecast evidence checked November 21, 2026.

Get free Keros Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$11.08
Average price target
$20.00
High price target
$25.00
Low price target
$16.00
Low target gap
+44.4%
Target upside
+80.5%
High target gap
+125.6%
Target range width
81.2%
Consensus rating
Buy
Analysts
6
Evidence date
November 21, 2026
Valid through
November 28, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Keros Therapeutics?

Keros Therapeutics has a verified Buy consensus. The same dataset has an average price target of $20.00.

How far are Keros Therapeutics's low and high targets from the recorded price?

The low target implies +44.4%, while the high target implies +125.6%.

How many analysts are included in Keros Therapeutics's consensus?

The verified consensus includes 6 analysts.

How is Keros Therapeutics's target upside or downside calculated?

The average target of $20.00 is divided by the recorded price of $11.08, then one is subtracted to produce +80.5%. This does not guarantee a future return.

When was Keros Therapeutics's analyst forecast verified?

The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.